Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease progression when added to the standard-of-care, Genentech’s ...

Niven Mehra discussing utilization of PARP inhibitors alone or in combination. Dr. Mehra started his presentation by emphasizing the importance of biomarker testing, given that many genes in the HRR ...

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...

Mutations in BRCA2 — a gene known to repair damaged DNA and suppress tumor formation — can predict an individuals' predisposition to develop breast cancer, ovarian, prostate, pancreatic, and other ...

Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...

which would really broaden the use of PARP inhibitors.” The phase 1 PETRA trial of AZD5305 has already begun in solid tumours and O’Connor said the drug will likely be used in cancers with ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Protocol in Place for Phase 3 Trial of IMNN-001 in Ovarian Cancer On ...

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

The new drug development corporation Daimbio announced on the 25th that it has completed a series A funding round worth 12 ...

Foghorn Therapeutics advances FHD-909 for SMARCA4 tumors, backed by Eli Lilly partnership. Read here to know why we are ...